YOLFTbeta
Vivesto AB

Vivesto AB

VIVE · ST · Healthcare / Drug Manufacturers - Specialty & Generic

7.20SEK-0.30 (-4.00%)

Price History

Full chart

Market Stats

Previous Close7.50
Open7.49
Day Range7.10 – 7.49
52-Week Range7.00 – 23.76
Volume9.83K
Market Cap87.24M
P/E (TTM)0.00
Forward P/E21.46
EPS-4.12
Dividend Yield0.00%
Beta0.88
50-Day Avg8.83
200-Day Avg8.98

About

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.
  • Employees4
  • HeadquartersGustav III:s Boulevard 46, Solna, Sweden, 169 73, Sweden
  • Websitehttps://www.vivesto.com

Leadership

  • Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.Chief Executive Officer · b. 1958
  • Mr. Björn SvanströmChief Financial Officer · b. 1971
  • Ms. Teresa Fernandez ZafraChief Scientific Officer & Head of Preclinical Development & Clinical Operations · b. 1987
  • Mr. Urban EkelundIR Manager
  • Mr. John T. CosbyHead of Regulatory Affairs · b. 1962
  • Mr. Dzianis BabrouHead of Product Development
  • Mr. Henrik RönnbergChief Medical Officer of Animal Health
  • Maria Nilsson HagbergHead of Regulatory Affairs
  • Ms. Johanna RostinChief Regulatory Officer · b. 1967
  • Ms. Kia BengtssonHead of Clinical Development · b. 1969

Financials

Income Statement

Currency: SEK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue11853.22K22.39M71.16M79.36M30.74M106.00K891.00K-60.00K2.07M6.37M172.00K3.17M1.98M201.84M201.84M26.19M1.01M000
Growth (%)-+7756463.64%+2523.82%+217.85%+11.52%-61.26%-99.66%+740.57%--+3350.00%+207.87%-97.30%+1742.44%-37.52%+10094.09%0.00%-87.02%-96.12%-100.00%--
Cost of Revenue-3.54M-5.07M8.19M35.63M20.53M-61.80M-69.93M-53.16M-42.50M-22.63M-6.74M-21.50M-2.63M-4.75M-3.81M-14.00M-14.00M44.12M11.67M03.19M-
Gross Profit3.54M5.93M14.20M35.52M58.82M92.54M70.03M54.05M42.50M22.69M8.80M27.88M2.81M7.92M5.79M215.84M215.84M-17.93M-10.66M0-3.19M-
Gross Margin32168400.00%694.43%63.41%49.92%74.12%301.04%66070.75%6065.77%-37815.00%425.36%437.41%1631.40%250.02%292.58%106.94%106.94%-68.46%-1049.85%---
Operating Expense6.87M12.84M23.60M40.38M65.98M107.50M134.39M119.58M110.08M120.78M117.03M160.57M143.29M111.65M125.92M245.93M245.93M110.72M346.06M132.17M38.77M-
Operating Income-3.33M-6.91M-9.40M-4.86M-7.16M-14.96M-64.35M-65.54M-67.58M-98.09M-108.22M-132.69M-140.48M-103.72M-120.13M-30.09M-30.09M-128.65M-356.72M-132.17M-41.96M-34.38M
Operating Margin-30261936.36%-810.05%-42.00%-6.82%-9.02%-48.67%-60710.38%-7355.33%--163485.00%-5228.26%-2082.08%-81675.00%-3273.08%-6067.27%-14.91%-14.91%-491.17%-35144.73%---
EBITDA3.02M-6.29M-8.41M-11.80M-40.03M-10.94M-59.20M-60.48M-64.32M-97.21M-102.90M-128.50M-142.25M-98.83M-113.53M-11.50M-11.50M-97.62M-89.76M-71.37M-36.56M-34.38M
EBITDA Margin27426590.91%-736.79%-37.58%-16.59%-50.44%-35.58%-55845.28%-6787.32%--162015.00%-4971.11%-2016.33%-82700.58%-3118.62%-5733.64%-5.70%-5.70%-372.72%-8843.15%---
Net Income2.51M-7.31M-9.76M-5.07M-7.11M-17.05M-65.96M-65.67M-72.38M-105.11M-117.50M-141.54M-160.24M-118.01M-171.02M-10.53M-10.53M-138.94M-367.03M-128.74M-39.75M-34.08M
Net Income Margin22776190.91%-856.40%-43.58%-7.12%-8.95%-55.48%-62226.42%-7370.37%--175186.67%-5676.18%-2220.92%-93164.53%-3723.79%-8637.37%-5.22%-5.22%-530.49%-36160.59%---
R&D--------------57.03M-88.59M-----
R&D as % of Total Revenue--------------2880.40%-43.89%-----
Interest Expense96.10K405.55K376.00K212.00K50.00K2.50M2.10M492.00K5.30M7.21M9.48M8.23M13.49M12.31M18.22M10.88M10.88M6.30M39.00K03.00K258.00K
Interest Expense % of Total Revenue873600.00%47.53%1.68%0.30%0.06%8.15%1978.30%55.22%-12020.00%458.07%129.20%7843.02%388.48%920.15%5.39%5.39%24.06%3.84%---

Balance Sheet

Currency: SEK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets36.06M63.69M120.79M87.67M97.10M179.65M320.32M349.81M445.18M468.38M514.57M515.58M521.58M568.08M646.38M1.01B863.54M594.31M355.88M220.67M172.88M149.04M
Total Liabilities4.66M4.80M10.50M22.86M35.89M37.85M26.15M76.33M126.03M186.48M138.86M189.53M221.21M223.04M222.33M185.96M176.80M44.59M30.45M22.87M14.55M24.46M
Total Equity31.40M58.90M110.18M64.72M61.11M141.75M294.17M273.47M319.15M281.91M375.71M326.05M300.37M345.04M424.05M819.39M-1.22B549.71M325.42M197.80M158.33M124.58M
Cash1.97M3.63M22.17M10.38M988.00K5.37M51.90M2.03M62.96M48.24M26.84M26.21M28.00M15.58M116.27M201.02M40.13M7.91M9.47M4.29M778.00K2.03M
Total Debt-2.94M2.46M14.49M26.83M14.84M-32.80M105.00M145.00M107.00M139.94M168.73M187.26M139.57M94.17M-10.43M8.17M--13.00M
Net Debt-1.97M-692.70K-19.71M4.11M25.84M9.47M-51.90M30.77M42.04M96.76M80.16M113.74M140.72M171.68M23.30M-106.85M-40.13M2.52M-1.30M-4.29M-778.00K10.97M

Cash Flow

Currency: SEK2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.53M-11.27M-22.73M9.00K14.28M-11.23M-57.60M-52.44M-69.54M-86.90M-107.67M-128.13M-133.01M-123.63M-118.84M-6.87M-204.86M-145.56M-80.52M-68.74M-47.25M-33.96M
Investing Cash Flow-5.61M-21.97M-19.83M-12.60M-39.51M-85.31M-98.66M-76.09M-59.80M-35.68M-69.75M10.07M12.04M-21.45M-14.03M-288.12M-21.55M118.65M-45.28M63.73M43.40M21.85M
Financing Cash Flow264.50K34.90M61.10M801.00K15.85M100.93M202.78M78.66M190.26M107.86M156.02M117.45M122.75M132.66M233.50M379.72M-6.01M-5.81M128.76M--13.00M
Capital Expenditure5.54M21.95M19.83M12.60M39.51M85.31M98.66M76.09M64.03M35.68M21.03M19.93M7.96M21.45M12.03M12.87M6.55M34.35M277.00K659.00K033.96M
Free Cash Flow994.21K-33.22M-42.56M-12.59M-25.23M-96.55M-156.26M-128.53M-133.57M-122.58M-128.69M-148.06M-140.97M-145.09M-130.87M-19.74M-211.41M-179.91M-80.79M-69.40M-47.25M-43.81M
FCF to OCF15.23%294.74%187.20%-139911.11%-176.75%859.36%271.30%245.10%192.08%141.06%119.53%115.56%105.98%117.35%110.12%287.49%103.20%123.60%100.34%100.96%100.00%129.01%

Earnings

Report DateSep 9, 2010Dec 9, 2010Mar 9, 2011Sep 8, 2011Dec 8, 2011Mar 8, 2012Jun 14, 2012Sep 6, 2012Dec 6, 2012Mar 1, 2013Jun 7, 2013Sep 6, 2013Dec 5, 2013Mar 6, 2014Jun 5, 2014Sep 5, 2014Dec 4, 2014Mar 5, 2015Jun 4, 2015Sep 3, 2015Dec 3, 2015Mar 3, 2016Jun 3, 2016Sep 2, 2016Dec 2, 2016Mar 3, 2017Jun 8, 2017Sep 1, 2017Dec 1, 2017Mar 2, 2018Jun 8, 2018Aug 31, 2018Nov 30, 2018Mar 1, 2019Sep 26, 2019Dec 30, 2019Mar 27, 2020Jun 18, 2020Sep 9, 2020Dec 9, 2020May 27, 2021Aug 19, 2021Nov 18, 2021Feb 24, 2022May 25, 2022Aug 25, 2022Nov 17, 2022Feb 23, 2023May 25, 2023Aug 24, 2023Nov 16, 2023Feb 22, 2024May 23, 2024Aug 22, 2024Nov 21, 2024Feb 20, 2025May 8, 2025Aug 12, 2025Nov 20, 2025Feb 27, 2026May 7, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-------------------------59.50-68.00---59.50-15.00---------0.12-0.10--0.09-0.09-0.09-0.09-0.06-----------------
EPS Actual-18.97-26.25-19.77-17.66-15.53-18.15-21.76-20.34-15.34-12.43-20.51-13.66-13.99-22.82-27.64-23.46-18.59-18.35-18.73-0.29-0.31-0.17-0.22-0.24-24.00-34.00-0.25-0.17-14.00-16.00-0.13-0.13-0.24-0.10-0.13-0.05-0.160.24-0.12-0.12-0.09-0.12-0.07-0.07-0.06-0.07-0.14-0.06-0.04-0.05-0.03-0.12-0.02-0.02-0.02-0.02-0.02-0.02-0.01-0.01-0.01-0.76-
Surprise------------------------59.66%50.00%--76.47%-6.67%--------0.00%-20.00%--33.33%22.22%22.22%33.33%-16.67%-----------------
Timing-------------------Pre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap87.24M
Enterprise Value108.66M
Trailing P/E0.00
Forward P/E21.46
Price / Sales10905.30
Price / Book0.62
EPS-4.12
Book Value0.232
Revenue (TTM)8.00K
Gross Profit (TTM)8.00K
EBITDA-30.79M
Profit Margin0.00%
Operating Margin-107825.00%
Return on Equity-21.10%
Return on Assets-12.24%
Shares Outstanding11.07M
Shares Float6.34M
Beta0.88
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 20, 20261:100